Search Results - "Lubbert, M."

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells by Flotho, C, Claus, R, Batz, C, Schneider, M, Sandrock, I, Ihde, S, Plass, C, Niemeyer, C M, Lübbert, M

“…The three DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues, azacitidine, decitabine and zebularine, which are currently studied as…”
Get full text

5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft by Steinmann, J, Bertz, H, Wäsch, R, Marks, R, Zeiser, R, Bogatyreva, L, Finke, J, Lübbert, M

“…DNA-hypomethylating agents are a viable treatment option for AML/myelodysplastic syndrome (MDS) relapse after allograft by upregulating Ags on blasts before…”
Get full text

The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO by Duque-Afonso, J, Yalcin, A, Berg, T, Abdelkarim, M, Heidenreich, O, Lübbert, M

“…The chromosomal translocation (8;21) fuses the hematopoietic transcription factor AML1 ( RUNX1 ) with ETO ( RUNX1T1, MTG8 ), resulting in the leukemia-specific…”
Get full text

Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS AML patients by Lübbert, M, Bertz, H, Rüter, B, Marks, R, Claus, R, Wäsch, R, Finke, J

“…Novel, non-intensive treatment options in older MDS/AML patients planned for allografting, with the goal of down-staging the underlying disease and bridging…”
Get full text

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting by Lübbert, M, Bertz, H, Wäsch, R, Marks, R, Rüter, B, Claus, R, Finke, J

“…We have piloted a low-dose schedule of 5-azacytidine followed by donor lymphocyte infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic…”
Get full text

Gene silencing of the p15 INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes? by Lubbert, M

Get full text

DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action by Lübbert, M

Get more information

Complementing mutations in core binding factor leukemias: from mouse models to clinical applications by Müller, A M S, Duque, J, Shizuru, J A, Lübbert, M

“…A great proportion of acute myeloid leukemias (AMLs) display cytogenetic abnormalities including chromosomal aberrations and/or submicroscopic mutations. These…”
Get full text

Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms by SCHMELZ, K, SATTLER, N, WAGNER, M, LÜBBERT, M, DÖRKEN, B, TAMM, I

“…The methylation inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR, decitabine) has therapeutic efficacy in acute myeloid leukemia (AML) and myelodysplastic syndrome…”
Get full text

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) by GERMING, U, HILDEBRANDT, B, STAUDE, R, GIAGOUNIDIS, A. A. N, STRUPP, C, KÜNDGEN, A, MUELLER, T, HAAS, R, GATTERMANN, N, AUL, C, PFEILSTÖCKER, M, NÖSSLINGER, T, VALENT, P, FONATSCH, C, LÜBBERT, M, HAASE, D, STEIDL, C, KRIEGER, O

“…The international prognostic scoring system (IPSS) is considered the gold standard for risk assessment in primary myelodysplastic syndromes (MDS). This score…”
Get full text

Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1 ETO-positive cells by Barbetti, V, Gozzini, A, Rovida, E, Morandi, A, Spinelli, E, Fossati, G, Mascagni, P, Lübbert, M, Dello Sbarba, P, Santini, V

“…We analysed the in vitro effects of a new hydroxamate derivative, ITF2357, on AML cells. ITF2357 potently induced histone acetylation. ITF2357 0.1 μ M blocked…”
Get full text

A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1 by Solari, L, Bauer, T, Dicker, F, Haferlach, C, Grießhammer, M, Schnittger, S, Becker, H, Lübbert, M

Get full text

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients by Wijermans, P W, Lübbert, M, Verhoef, G, Klimek, V, Bosly, A

“…During the last 10 years, three European phase II studies were performed to investigate the treatment of elderly patients with myelodysplastic syndrome (MDS)…”
Get full text

Epigenetic lesions in malignant melanoma by Schwabe, M, Lübbert, M

“…Malignant melanoma arises through a series of genetic and epigenetic events. A more profound understanding of the biology of metastatic melanoma should greatly…”
Get more information

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine by LÜBBERT, Michael, WIJERMANS, Pierre, KUNZMANN, Regina, VERHOEF, Gregor, BOSLY, Andre, RAVOET, Christophe, ANDRE, Marc, FERRANT, Augustin

“…Decitabine (5-aza-2'-deoxycytidine) acts as a powerful demethylating agent in vitro. Clinically, low-dose decitabine ameliorates cytopenias including induction…”
Get full text

Susceptibility of Nonpromoter CpG Islands to De Novo Methylation in Normal and Neoplastic Cells by Nguyen, Carvell, Liang, Gangning, Nguyen, TuDung T., Tsao-Wei, Denice, Groshen, Susan, Lübbert, Michael, Zhou, Jain-Hua, Benedict, William F., Jones, Peter A.

“…Background: Many cancers display alterations in methylation patterns of CpG islands—stretches of DNA rich in CpG dinucleotides often associated with gene…”
Get full text

Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up by Rückert, A, Glimm, H, Lübbert, M, Grüllich, C

“…An association of antiphospholipid antibody syndrome with antibodies directed against either phospholipids or plasma proteins strongly suggest that B-cell…”
Get full text

34 Which myelodysplastic syndromes patients are candidates for treatment with decitabine? by Lubbert, M

Get full text

CD34+ or CD34-: which is the more primitive? by ENGELHARDT, M, LÜBBERT, M, GUO, Y

“…Remarkable progress has been achieved in the characterization and isolation of primitive hematopoietic stem cells (HSC). HSC represent a very small subset of…”
Get full text

Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib by Chevalier, N, Solari, M L, Becker, H, Pantic, M, Gärtner, F, Maul-Pavicic, A, Hübner, J, Wäsch, R, Schmitt-Gräff, A, Lübbert, M

Get full text